Development of a syngenic murine B16 cell line-derived melanoma susceptible to destruction by neuroattenuated HSV-1

Molecular Therapy

Volumn 3, Issue 2, 2001, Pages 160-168

  Miller, Cathie G ^a   Krummenacher, Claude ^a   Eisenberg, Rosalyn J ^a   Cohen, Gary H ^a   Fraser, Nigel W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Gene therapy; HSV 1; Hve receptor; Melanoma; Tumor model

Indexed keywords

HERPES VIRUS ENTRY RECEPTOR A; HERPES VIRUS ENTRY RECEPTOR B; HERPES VIRUS ENTRY RECEPTOR C; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MUTANT; NONHUMAN; PLASMID; REPRODUCIBILITY; SURVIVAL TIME; VIRUS ATTENUATION;

ANIMALIA; HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; MURINAE; RODENTIA;

EID: 0034986067     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0240     Document Type: Article

References (64)

1. The case for radiosurgery
2. Fotemustine and interferon alpha2b in metastatic malignant melanoma
3. Experimental therapy of human glioma by means of a genetically engineered virus mutant
4. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant
5. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors
6. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus
7. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
8. Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model
9. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family
10. A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus
11. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor
12. The ectodomain of a novel member of the immunoglobulin subfamily related to the poliovirus receptor has the attributes of a bona fide receptor for herpes simplex virus types 1 and 2 in human cells
13. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant
14. Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS
15. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity
16. Long-term survival of rats harboring brain neoplasms treated with a herpes simplex virus vector that retains an intact thymidine kinase gene
17. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma
18. A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma
19. Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: Results of a phase 1 trial
20. Toxicity evaluation of replication competent herpes simplex virus (IC34.5 null mutant 1716) in patients with recurrent malignant glioma
21. Recombinant vaccinia virus expressing cytokine GM-CSF as tumor vaccine
22. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine
23. Efficient in vivo targeting of malignant melanoma by single-chain Fv antibody fragments
24. The effect of various types of splenectomy on the development of B-16 melanoma in mice
25. Establishment of four functional, clonal strains of animal cells in culture
26. Membrane fusion induced by herpes simplex virus
27. The V domain of herpesvirus Ig-like receptor (HIgR) contains a major functional region in herpes simplex virus-1 entry into cells and interacts physically with the viral glycoprotein D
28. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1
29. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation
30. ATAR, a novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5
31. The human poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic adhesion molecule
32. The human PRR2 gene, related to the human poliovirus receptor gene (PVR), is the true homolog of the murine MPH gene
33. Nectin/PRR: An immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through interaction with Afadin, a PDZ domain-containing protein
34. Complementary DNA characterization and chromosomal localization of a human gene related to the poliovirus receptor-encoding gene
35. Investigation of herpes simplex virus type 1 genes encoding multiply inserted membrane proteins
36. Detection of herpes simplex type 1 transcripts during latent infection in mice
37. Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry
38. Herpes simplex virus glycoprotein D can bind to poliovirus receptor-related protein 1 or herpesvirus entry mediator, two structurally unrelated mediators of virus entry
39. In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity
40. Transcriptional targeting of herpes simplex virus for cell-specific replication
41. CNS tumor therapy by attenuated herpes simplex viruses
42. Treatment of malignant gliomas using ganciclovir hypersensitive, ribonucleotide reductase deficient herpes simplex viral mutant
43. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates
44. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product
45. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus (HSV), and retrovirus vectors
46. Suicide gene therapy of chemically induced mammary tumor in rat: Efficacy and distant bystander effect
47. Gene therapy of malignant brain tumors: A rat glioma line bearing the herpes simplex virus type 1 thymidine kinase gene and wild type retrovirus kills other tumor cells
48. Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector
49. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment
50. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant
51. Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma
52. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells
53. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer
54. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer
55. Effects of herpes simplex virus on human oral cancer cells, and potential use of mutant viruses in therapy of oral cancer
56. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant
57. Treatment of cerebral metastasis with herpes simplex virus one mutant 1716: Culture and animal studies
58. Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines
59. Inhibition of herpes simplex virus gD and lymphotoxin-alpha binding to HveA by peptide antagonists
60. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth
61. Mouse homolog of poliovirus receptor-related gene 2 product, mPRR2, mediates homophilic cell aggregation
62. The murine homolog (Mph) of human herpesvirus entry protein B (HveB) mediates entry of pseudorabies virus but not herpes simplex virus types 1 and 2
63. The murine homolog of human Nectin1delta serves as a species nonspecific mediator for entry of human and animal alpha herpesviruses in a pathway independent of a detectable binding to gD
64. Three classes of cell surface receptors for alphaherpesvirus entry